albuterol / budesonide vs Vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Beta-2 adrenergic receptor · full Asthma pipeline
albuterol / budesonide · Airsupra
Marketed by AstraZeneca
NCT03769090 · Phase 3 · completed
Participants were randomized and quadruple-blinded across two budesonide/albuterol groups and an active albuterol comparator, with 3,132 randomized participants. The primary clinical endpoint was met for both doses: severe exacerbations occurred in 207/1,013 versus 266/1,014 participants for high-dose treatment (hazard ratio 0.733, p<0.001) and 241/1,054 versus 276/1,056 for low-dose treatment (hazard ratio 0.835, p=0.041).
Next expected readout: February 2027 · NCT06422689 (registry estimate)
Reported efficacy
Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): Time to First Severe Asthma Exacerbation, While on Treatment Strategy, Interim Analysis Data Cut-off (Participants Aged >=12 Years) (From treatment initiation until the earliest occurrence of study completion, treatment discontinuation, step-up in maintenance therapy, or interim analysis DCO, up to one year following treatment initiation.): BDA MDI (PT027) 160/180 μg 62/1209 vs AS MDI (PT007) 180 µg 110/1212 (met)
Result source: NCT05505734
Vilanterol
Developed by GlaxoSmithKline
NCT00381667 · Phase 2 · completed
The study was randomized, double-blind, and placebo-controlled, but enrolled only 14 participants. Its primary outcomes included lung-function and safety measurements rather than a hard clinical endpoint, and the primary comparison cannot be assessed because results have not been posted.
Reported efficacy
Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): Mean Change From Baseline in Clinic Visit Trough FEV1 at Day 28 (Last Observation Carried Forward [LOCF]) (Baseline and Day 28): GW642444M 3 µg 0.212 Liters (Standard Error 0.036) | GW642444M 6.25 µg 0.217 Liters (Standard Error 0.035) | GW642444M 12.5 µg 0.278 Liters (Standard Error 0.036) | GW642444M 25 µg 0.269 Liters (Standard Error 0.035) | GW642444M 50 µg 0.309 Liters (Standard Error 0.035) vs Placebo 0.147 Liters (Standard Error 0.036) (mixed)
Result source: NCT00600171
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | albuterol / budesonide | Vilanterol |
|---|---|---|
| Severe exacerbations, annualised rate | 0.5 vs 0.6vs AS MDINCT037690902 other results
| —Not reported |
| Trough FEV1, change | 0.1 vs 0.0+0.1 vs placeboNCT038478963 other results
| 0.3 vs 0.1+0.1 vs placeboNCT006001718 other results
|
| ACQ-5, change | —Not posted · NCT06502366 | —Not reported |
| OCS dose reduction | —Not posted · NCT06502366 | —Not reported |
Severe exacerbations, annualised rate
- albuterol / budesonide
- 0.5 vs 0.6vs AS MDINCT03769090
2 other results
- 0.1 vs 0.3 NCT05505734
- 0.1 vs 0.3 NCT05505734
- Vilanterol
- —Not reported
Trough FEV1, change
- albuterol / budesonide
- 0.1 vs 0.0+0.1 vs placeboNCT03847896
3 other results
- 0.1 vs 0.0 NCT03847896
- 0.1 vs 0.0 NCT03847896
- 0.1 vs 0.0 NCT03847896
- Vilanterol
- 0.3 vs 0.1+0.1 vs placeboNCT00600171
8 other results
- 0.3 vs 0.1 NCT00600171
- 0.3 vs 0.1 NCT00600171
- 0.2 vs 0.1 NCT00600171
- 0.2 vs 0.1 NCT00600171
- -0.5 vs -0.8 NCT01128569
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
ACQ-5, change
- albuterol / budesonide
- —Not posted · NCT06502366
- Vilanterol
- —Not reported
OCS dose reduction
- albuterol / budesonide
- —Not posted · NCT06502366
- Vilanterol
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. albuterol / budesonide: 4 of 4 rows · Vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | albuterol / budesonide | Vilanterol |
|---|---|---|
| Dropout rate | 9.9%160/180 μga NCT03769090 · Phase 3 · Asthma · phase 3 show 8 more results11.7%80/180 μg NCT03769090 · Phase 3 · Asthma · phase 3 28.2%160/180 μg NCT05505734 · Phase 3 · Asthma · phase 3 3.6%160/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 7.8%80/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 —160/180 NCT06245551 · Phase 3 — NCT05555290 · Phase 3 · registry result, not featured evidence — NCT04234464 · Phase 3 · registry result, not featured evidence —160/180 μg NCT04848662 · Phase 1 · registry result, not featured evidence | 7.9%25 µgb NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results4.9%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 9.9%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 16.8%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12.2%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence 21.1%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 12.4%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 18.4%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —25 µg NCT01453296 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 0.7%160/180 μga NCT03769090 · Phase 3 · Asthma · phase 3 show 8 more results0.7%80/180 μg NCT03769090 · Phase 3 · Asthma · phase 3 0.5%160/180 μg NCT05505734 · Phase 3 · Asthma · phase 3 1%160/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 0.5%80/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 —160/180 NCT06245551 · Phase 3 — NCT05555290 · Phase 3 · registry result, not featured evidence — NCT04234464 · Phase 3 · registry result, not featured evidence —160/180 μg NCT04848662 · Phase 1 · registry result, not featured evidence | 1%25 µgb NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results0%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 1%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0.9%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence 0.9%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence —25 µg NCT01453296 · Phase 2 · registry result, not featured evidence —100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 5.2%160/180 μga NCT03769090 · Phase 3 · Asthma · phase 3 show 8 more results3.8%80/180 μg NCT03769090 · Phase 3 · Asthma · phase 3 3.1%160/180 μg NCT05505734 · Phase 3 · Asthma · phase 3 1%160/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 2%80/180 μg NCT03847896 · Phase 3 · Asthma · phase 3 0%160/180 NCT06245551 · Phase 3 0% NCT05555290 · Phase 3 · registry result, not featured evidence 0% NCT04234464 · Phase 3 · registry result, not featured evidence 0%160/180 μg NCT04848662 · Phase 1 · registry result, not featured evidence | 0%25 µgb NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 16 more results0%50 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%12.5 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%6.25 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0%3 µg NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 0.9%25 µg OD NCT01181895 · Phase 3 · registry result, not featured evidence —25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%100/25 µg AM NCT01287065 · Phase 2 · registry result, not featured evidence 0%100/25 µg PM NCT01287065 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128595 · Phase 2 · registry result, not featured evidence 0%25 µg NCT01453296 · Phase 2 · registry result, not featured evidence 0%100/25 µg OD NCT01128569 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | show 8 more results160/180 μg upper respiratory tract infection 5.4% covid-19 5.1% nasopharyngitis 3.7% NCT05505734 · Phase 3 · Asthma · phase 3 160/180 μg nasopharyngitis 7.6% (placebo 5.5%) headache 5.1% (placebo 7%) dysphonia 2% (placebo 0%) NCT03847896 · Phase 3 · Asthma · phase 3 80/180 μg nasopharyngitis 6.4% (placebo 5.5%) headache 4.9% (placebo 7%) upper respiratory tract infection 1.5% (placebo 1%) NCT03847896 · Phase 3 · Asthma · phase 3 160/180 bronchial irritation 1.6% (placebo 0%) diarrhoea 0% (placebo 1.6%) headache 0% (placebo 1.6%) NCT06245551 · Phase 3 anxiety 0% (placebo 1.7%) dyspnoea 0% (placebo 1.7%) NCT04234464 · Phase 3 · registry result, not featured evidence | 25 µgb headache 6.9% (placebo 7.8%) upper respiratory tract infection 2% (placebo 2%) nasopharyngitis 0% (placebo 3.9%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 show 13 more results50 µg headache 7.8% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 2% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 12.5 µg headache 9% (placebo 7.8%) upper respiratory tract infection 3% (placebo 2%) nasopharyngitis 0% (placebo 3.9%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 6.25 µg headache 6.9% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 1% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 3 µg headache 11.9% (placebo 7.8%) nasopharyngitis 2% (placebo 3.9%) upper respiratory tract infection 2% (placebo 2%) NCT00600171 · Phase 2 · monotherapy · Asthma · phase 2 25 µg OD headache 8.7% (placebo 4.3%) nasopharyngitis 7.8% (placebo 10.3%) oropharyngeal pain 5.2% (placebo 6%) NCT01181895 · Phase 3 · registry result, not featured evidence 12.5 OD nasopharyngitis 8.8% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 25 OD nasopharyngitis 7.9% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 6.25 OD nasopharyngitis 7% (placebo 7%) headache 5.3% (placebo 3.5%) influenza 3.5% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 100/25 µg AM headache 25% (placebo 26.1%) nasopharyngitis 12.5% (placebo 13%) dysmenorrhoea 4.2% (placebo 0%) NCT01287065 · Phase 2 · registry result, not featured evidence 100/25 µg PM headache 32% (placebo 26.1%) gastroenteritis 8% (placebo 0%) nasopharyngitis 8% (placebo 13%) NCT01287065 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 55.6% (placebo 40.7%) nasopharyngitis 11.1% (placebo 7.4%) oropharyngeal pain 11.1% (placebo 7.4%) NCT01128595 · Phase 2 · registry result, not featured evidence 25 µg upper respiratory tract infection 11.1% (placebo 0%) headache 7.4% (placebo 7.7%) pyrexia 7.4% (placebo 0%) NCT01453296 · Phase 2 · registry result, not featured evidence 100/25 µg OD headache 9.8% (placebo 17.6%) dysphonia 3.9% (placebo 0%) mouth ulceration 3.9% (placebo 0%) NCT01128569 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 4 of these studies.
- bPopulation comparability has not been reviewed for 12 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
albuterol / budesonide
show 2 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
+ 12 further endpoints in the CSV export.
Vilanterol
show 9 more results
show 5 more results
show 5 more results
show 4 more results
show 4 more results
show 2 more results
show 3 more results
show 3 more results
show 5 more results
show 5 more results
show 1 more result
+ 8 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: albuterol / budesonide's landscape · Vilanterol's landscape